Hunan Jiudian Pharmaceutical Co Ltd (300705) - Total Liabilities
Based on the latest financial reports, Hunan Jiudian Pharmaceutical Co Ltd (300705) has total liabilities worth CN¥1.02 Billion CNY (≈ $148.58 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hunan Jiudian Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300705 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Hunan Jiudian Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hunan Jiudian Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ridley Corporation Ltd
AU:RIC
|
Australia | AU$1.10 Billion |
|
Shanghai Pudong Road & Bridge Construction Co Ltd
SHG:600284
|
China | CN¥22.52 Billion |
|
Maccura Biotechnology Co Ltd
SHE:300463
|
China | CN¥1.68 Billion |
|
Ferrari Group PLC
AS:FERGR
|
Netherlands | €117.94 Million |
|
PennantPark Floating Rate Capital Ltd
NYSE:PFLT
|
USA | $1.71 Billion |
|
Southern Missouri Bancorp Inc
NASDAQ:SMBC
|
USA | $4.57 Billion |
|
Zhejiang Zanyu Technology Co Ltd
SHE:002637
|
China | CN¥4.75 Billion |
|
Harvia Oyj
HE:HARVIA
|
Finland | €140.74 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Hunan Jiudian Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300705 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Jiudian Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Jiudian Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total liabilities of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥846.40 Million ≈ $123.86 Million |
-5.74% |
| 2023-12-31 | CN¥897.93 Million ≈ $131.40 Million |
+20.20% |
| 2022-12-31 | CN¥747.05 Million ≈ $109.32 Million |
+15.66% |
| 2021-12-31 | CN¥645.90 Million ≈ $94.52 Million |
+118.92% |
| 2020-12-31 | CN¥295.04 Million ≈ $43.17 Million |
-4.90% |
| 2019-12-31 | CN¥310.23 Million ≈ $45.40 Million |
+37.85% |
| 2018-12-31 | CN¥225.05 Million ≈ $32.93 Million |
+106.57% |
| 2017-12-31 | CN¥108.95 Million ≈ $15.94 Million |
+48.02% |
| 2016-12-31 | CN¥73.60 Million ≈ $10.77 Million |
+15.35% |
| 2015-12-31 | CN¥63.81 Million ≈ $9.34 Million |
+8.69% |
| 2014-12-31 | CN¥58.71 Million ≈ $8.59 Million |
-23.06% |
| 2013-12-31 | CN¥76.30 Million ≈ $11.17 Million |
-- |
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Pat… Read more